Pembrolizumab Plus Chemotherapy Approved for Patients With HER2-Negative Gastric or Gastroesophageal Junction Cancer
Recommended
Pembrolizumab Plus Chemotherapy Approved for Patients With HER2-Negative Gastric or Gastroesophageal Junction Cancer
The US Food and Drug Administration (FDA) has approved pembrolizumab plus fluoropyrimidine- and platinum-containing chemotherapy for the first-line treatment of patients with locally advanced unresectable or metastatic HER2-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma.
Access the full article to read more here.
<!-- BEGIN ADVERTSERVE CODE -->
<div id="mobile_block_ad_1"><script type="text/javascript">
var _avp = _avp || [];
_avp.push({ tagid: 'mobile_block_ad_1', alias: '/', type: 'banner', zid: 1669, pid: 0, onscroll: 0, inview: true, secure: true });
</script></div>
<!-- END ADVERTSERVE CODE -->